Compound: Nomifensine
SMILES: N1(Cc2c(N)cccc2C(C1)c3ccccc3)C
InChIKey: XXPANQJNYNUNES-UHFFFAOYSA-N
Synonyms: Nomifensine, 24526-64-5, nomifensin, Linamiphen, (+-)-Nomifensin, (+-)-Nomifensine, Nomifensina, Nomifensinum, 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-, D,L-nomifensine, 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, 2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine, 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine, 1LGS5JRP31, DTXSID0023377, Isoquinoline, 1,2,3,4-tetrahydro-8-amino-2-methyl-4-phenyl-, DTXCID803377, CHEBI:116225, RefChem:166402, N06AX04, 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine, MFCD00242716, CHEMBL273575, Nomifenison, Nomifensinum [INN-Latin], Nomifensina [INN-Spanish], (+/-)-Nomifensine maleat, Nomifensine [INN:BAN], Nomiphensine, R/S-nomifensine, CCRIS 9179, (+/-)-Nomifensin, (+/-)-Nomifensine, Nomifensine maleate(USAN), UNII-1LGS5JRP31, 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisochinolin, 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline, HSDB 7702, ()-Nomifensine maleat, 1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine, 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine, Spectrum_000899, NOMIFENSINE [MI], Prestwick0_000108, Prestwick1_000108, Prestwick2_000108, Prestwick3_000108, Spectrum2_001548, Spectrum3_000963, Spectrum4_001079, Spectrum5_001004, NOMIFENSINE [INN], NOMIFENSINE [HSDB], Lopac0_000875, SCHEMBL49380, BSPBio_000096, BSPBio_002565, KBioGR_001438, KBioSS_001379, NOMIFENSINE [WHO-DD], DivK1c_000789, SPBio_001396, SPBio_002035, BPBio1_000106, GTPL4792, orb1299934, 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine(Nomifensine), SCHEMBL29355061, KBio1_000789, KBio2_001379, KBio2_003947, KBio2_006515, KBio3_001785, NINDS_000789, HY-B1110, Isoquinoline, 8-amino-1,2,3,4-tetrahydro-2-methyl-4-phenyl-, Tox21_301755, BDBM50005548, EBC-08728, EX-A10994, 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine 2-butenedioate, AKOS015919487, CCG-204957, CS-4708, DB04821, SDCCGSBI-0050850.P004, IDI1_000789, NCGC00015727-03, NCGC00015727-04, NCGC00015727-06, NCGC00015727-07, NCGC00015727-15, NCGC00089794-02, NCGC00255316-01, AC-31222, BS-22102, DA-18354, SBI-0050850.P003, CAS-24526-64-5, AB00053664, NS00099754, AB00053664_13, AB00053664_14, EN300-7376971, L001242, Q409948, BRD-A29644307-050-05-5, BRD-A29644307-050-10-5, BRD-A29644307-050-16-2, BRD-A29644307-050-17-0, BRD-A29644307-050-18-8, 2-Methyl-4-phenyl-1,2,3,4-tetrahydroquinolin-8-amine, Z2216900850, 8-amino-4-phenyl-2-methyl-1,2,3,4-tetrahydro-isoquinoline, (+)-2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine, (+/-)-2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine, (-)-2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine, 2-METHYL-4-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLIN-8-YLAMINE, (Nomifensine) 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine, 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine (Nomifensine), NOMIFENSINE2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine, 2-Methyl-4-phenyl-1 pound not2 pound not3 pound not4-tetrahydroisoquinolin-8-amine, 118184-50-2
Theoretical properties:
molecular_formula: C16H18N2
molecular_weight: 238.33 g/mol
exact_mass: 238.146998583 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 1
heavy_atom_count: 18
topological_polar_surface_area: 29.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Nomifensine is an N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively. It has a role as a dopamine uptake inhibitor.
chebi: An <em>N</em>-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
chembl: NOMIFENSINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Nomifensine, formerly sold under the brand names Merital and Alival, is a norepinephrine–dopamine reuptake inhibitor (NDRI) drug that was developed in the 1960s by Hoechst AG (now Sanofi-Aventis), who then test marketed it in the United States. 
Nomifensine was considered an effective antidepressant that lacked sedative effects. It did not interact significantly with alcohol and lacked anticholinergic effects. No withdrawal symptoms were seen after 6 months treatment. The drug was, however, considered not suitable for agitated patients as it presumably made agitation worse. In January 1986 the drug was withdrawn by its manufacturers for safety reasons.
Some case reports in the 1980s suggested that there was potential for psychological dependence on nomifensine, typically in patients with a history of stimulant addiction, or when the drug was used in very high doses (400–600 mg per day).
In a 1989 study it was investigated for use in treating attention deficit hyperactivity disorder (ADHD) in adults and was proven to be effective. In a 1977 study it was not proven of benefit in advanced parkinsonism, except for depression associated with the parkinsonism.